{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.34","value":"48400"},{"groupId":"OG001","spread":"0.48","value":"34000"},{"groupId":"OG002","spread":"0.09","value":"45000"},{"groupId":"OG003","spread":"0.30","value":"49700"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Vz/F was defined as the apparent volume of distribution of INCB001158.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose","title":"Vz/F of INCB001158 Following Multiple Escalating Doses for Part 1A","type":"SECONDARY","unitOfMeasure":"Liters"}